Analyst Reco. Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Market Closed - Toronto S.E. Other stock markets 03:59:29 2024-06-03 pm EDT			5-day change	1st Jan Change
1.33 ^CAD	-0.75%		-17.39%	-60.30%

11:12pm	Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	MT
May. 31	Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	Nov. 10	MT
Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	23-08-11	MT
HC Wainwright & Co. Adjusts Price Target on Aptose Biosciences to $23 From $12, Maintains Buy Rating	23-08-11	MT
RBC Cuts Price Target on Aptose Biosciences to $23 From $40, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
Piper Sandler Initiates Aptose Biosciences at Overweight Rating With $37 Price Target	23-06-12	MT
Oppenheimer Adjusts Aptose Biosciences Price Target to $50 From $9, Maintains Outperform Rating	23-06-12	MT
Piper Sandler Adjusts Aptose Biosciences' Price Target to $37 From $45, Keeps Overweight Rating	23-06-07	MT
RBC Adjusts Price Target on Aptose Biosciences to $40 From $75 Amid Reverse Stock Split, Keeps Outperform, Speculative Risk	23-06-07	MT
RBC Capital Maintains Outperform/Speculative Rating, US$5 Target on Aptose Biosciences After Q1	23-05-09	MT
Canaccord Genuity Adjusts Aptose Biosciences Price Target to $8 From $13, Maintains Buy Rating	23-03-27	MT
RBC Trims Aptose Biosciences' Price Target to $5 From $6, Keeps Outperform Rating, Speculative Risk Qualifier	22-11-02	MT
RBC Capital Maintains Outperform/Speculative Risk Rating, US$6 TP on Aptose Biosciences After CFO Appointment	22-06-28	MT
RBC Cuts Price Target on Aptose Biosciences to $6 From $7, Maintains Outperform Rating, Speculative Risk Qualifier	22-05-10	MT
RBC Capital Keeps Outperform/Speculative Risk, US$7 TP on Aptose Biosciences After Q4 Results	22-03-23	MT
RBC Capital Keeps Outperform/Speculative Risk Rating, US$7 TP on Aptose Biosciences	22-01-11	MT
RBC Cuts Price Target on Aptose Biosciences to $7 From $9, Maintains Outperform Rating, Speculative Risk Qualifier	22-01-06	MT
HC Wainwright Adjusts Aptose Biosciences' Price Target to $12 From $14, Keeps Buy Rating	21-12-21	MT
RBC Capital Reiterates Outperform/Speculative Risk Rating, US$9 TP on Aptose Biosciences	21-12-14	MT
RBC Capital Markets Keeps Rating on Aptose Biosciences Unchanged After "Uneventful" Q3 Earnings Call	21-11-12	MT
HC Wainwright Adjusts Aptose Biosciences' Price Target to $14 From $9, Reiterates Buy Rating	21-11-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Analyst Reco.

Filters